 we report on our financial results for the fourth quarter and full year of 2020 and provide an outlook for the remainder of the year and beyond. 
 this is our first earnings conference call and our 2020 annual business update. in 2020, we grew our revenue by 20-fold to $233 million from a loss of $2 million in the fourth quarter of last year. 
 we also continued to invest in our platform and build capacity, including almost doubling our headcount and acquiring key technologies, including a proprietary humanized rodent platform and a bispecific engineering platform. in 2020, we were successful in multiple rounds of financing raising the net total of $684 million. this includes the $523 million raised from our December IPO, as well as $75 million raised from our convertible note issuance earlier in the year that supported the acquisition of Trianni. 
 these inflows allowed us to make significant investments in technology and facilities to strengthen our technology platform and to expand our capabilities to pursue new therapeutic programs. 
 we also secured funding for and began work on the buildup of our manufacturing capabilities. 
 we ended the year with nearly $600 million in cash and over $200 million in accounts receivable. 
 this provides a strong cash position with which we will